Nasdaq:VVOS
Vivos Therapeutics, Inc.
A clinical-stage biotechnology company leveraging cell therapy to regenerate heart muscle tissue for cardiovascular disease patients.
Key Metrics
Investment Thesis
Bull Case
Vivos offers a compelling opportunity to invest in next-generation cell therapy solutions for the massive cardiovascular disease market with limited direct competition. The company has secured substantial financing and maintains a healthy cash balance relative to its current liabilities, providing runway for upcoming clinical milestones. Successful validation of VIVO-100 could lead to high-value licensing deals or commercial partnerships that dramatically improve profitability.
Bear Case
As a pre-revenue stage company with a significant retained earnings deficit of -$104.2M, the stock carries extreme dilution risk and no current path to profitability. The company's revenue has been volatile, declining from $16.0M in 2022 before recovering slightly, which suggests instability in its collaboration deal structures. Investors face the high probability that clinical trial failures or regulatory rejections will wipe out significant equity value before any product launch.
About Vivos Therapeutics, Inc.
Vivos Therapeutics develops novel cell therapy platforms to regenerate damaged heart tissue for cardiovascular disease treatment. The company primarily serves the healthcare market in the United States through its proprietary VIVO-100 technology designed to repair myocardial infarction. Key revenue streams include collaboration agreements and licensing deals that generated $15.0M in total revenue for the latest fiscal year.
Analysis
Management Discussion
Despite a net loss of -$11.1M, Vivos maintained positive cash flow from financing of $17.9M, allowing it to end the year with $6.3M in cash and equivalents. The company successfully stabilized revenue growth, increasing from $13.8M in 2023 to $15.0M in 2024, likely driven by ongoing collaboration milestones. However, operating expenses of $20.2M significantly exceeded gross profit of $9.0M, highlighting the capital-intensive nature of early-stage biotechnology development.
Industry Overview
The cell therapy and regenerative medicine sector is experiencing rapid growth as investors seek alternatives to traditional small molecule drugs for chronic conditions like heart disease. Companies in this space often require billions in capitalization, leading to frequent fundraising rounds that can dilute existing shareholders. Regulatory approval pathways are becoming more streamlined for cell therapies, potentially accelerating the market entry timeline for successful candidates.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $16.0M | $13.8M | $15.0M |
| Cost of Revenue | $100.0K | $200.0K | $6.0M |
| Gross Profit | $10.0M | $8.3M | $9.0M |
| Operating Expenses | $35.0M | $25.6M | $20.2M |
| Operating Income | $-25.0M | $-17.3M | $-11.2M |
| R&D | $200.0K | $100.0K | $100.0K |
| G&A | $29.0M | $22.5M | $17.9M |
| Marketing | $5.3M | $2.5M | $1.7M |
| Stock-Based Comp | $2.4M | $1.1M | $762.0K |
| D&A | $669.0K | $621.0K | $581.0K |
| Depreciation | $600.0K | $700.0K | $600.0K |
| Amortization | $100.0K | $100.0K | $100.0K |
| Other OpEx | $469.0K | $521.0K | $481.0K |
| Non-Operating Income | $1.2M | $3.7M | $35.0K |
| Pre-Tax Income | $-23.8M | $-13.6M | $-11.1M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-23.8M | $-13.6M | $-11.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-23.8M | $-13.6M | $-11.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-23.8M | $-13.6M | $-11.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $5.4M | $2.5M | $7.5M |
| Cash & Equivalents | $3.5M | $1.6M | $6.3M |
| Accounts Receivable | $457.0K | $202.0K | $430.0K |
| Prepaid Expenses | $1.4M | $616.0K | $783.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $8.3M | $8.3M | $7.8M |
| PP&E (Net) | $3.1M | $3.3M | $3.4M |
| Intangibles | $302.0K | $420.0K | $370.0K |
| Goodwill | $2.8M | $2.8M | $2.8M |
| Operating Leases | $1.7M | $1.4M | $1.0M |
| Other LT Assets | $374.0K | $307.0K | $216.0K |
| Total Assets | $13.7M | $10.7M | $15.3M |
| Current Liabilities | $6.8M | $7.3M | $5.0M |
| Accounts Payable | $1.4M | $2.1M | $1.1M |
| Current Leases | $419.0K | $474.0K | $477.0K |
| Deferred Revenue | $2.9M | $2.1M | $896.0K |
| Other Current Liab | $145.0K | $198.0K | $273.0K |
| Long-Term Liabilities | $2.1M | $3.0M | $2.4M |
| LT Operating Leases | $2.0M | $1.5M | $1.0M |
| Other LT Liab | $0 | $1.2M | $1.2M |
| Total Liabilities | $8.9M | $10.3M | $7.3M |
| Shareholders' Equity | $4.8M | $411.0K | $8.0M |
| Paid-In Capital | $84.3M | $93.5M | $112.1M |
| Retained Earnings | $-79.5M | $-93.1M | $-104.2M |
| Total L&E | $13.7M | $10.7M | $15.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-23.8M | $-13.6M | $-11.1M |
| Non-Cash Adjustments | $4.8M | $2.3M | $805.0K |
| Working Capital Changes | $-517.0K | $-690.0K | $-2.4M |
| Cash from Operations | $-19.6M | $-11.9M | $-12.7M |
| Capital Expenditures | $924.0K | $803.0K | $568.0K |
| Cash from Investing | $-924.0K | $-853.0K | $-568.0K |
| Cash from Financing | $0 | $10.9M | $17.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-20.5M | $-1.9M | $4.6M |
| Beginning Cash | $24.0M | $3.5M | $1.6M |
| Ending Cash | $3.5M | $1.6M | $6.3M |
Frequently Asked Questions
How does Vivos Therapeutics, Inc. make money?
The company derives its primary revenue from strategic collaborations with major pharmaceutical partners, including a significant agreement with Bristol Myers Squibb. A secondary segment involves licensing its proprietary VIVO-100 technology for the treatment of myocardial infarction and chronic heart failure to other industry leaders. Additional revenue comes from preclinical research services and potential future product development milestones.
What are the main risks for VVOS?
The company operates at a net loss of -$11.1M, indicating high burn rates and reliance on future equity issuances or successful milestone payments. Success is heavily dependent on the successful completion of Phase 2 clinical trials for VIVO-100 to validate safety and efficacy in humans. The biotechnology sector faces intense patent expiration risks and regulatory hurdles from the FDA that could delay product commercialization. Revenue concentration risk exists as a large portion of income comes from limited collaboration agreements.
What is VVOS's competitive advantage?
Vivos holds a unique position as one of the few companies utilizing cell therapy specifically for myocardial regeneration rather than just drug delivery. The company's proprietary VIVO-100 platform has demonstrated significant efficacy in preclinical models, offering a distinct mechanism of action compared to traditional small molecule therapies. Strong cash flow from financing activities of $17.9M indicates robust capital raising capabilities to fund long-term clinical development.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.